

REFERENCES

REFERENCES

- [1] Laowsombat, W. (2541). **Thalassemia**, 129. Bangkok: O.S.Printing Hous
- [2] Chern, J.P.S., Lin, K.H., Lu, M.Y., Lin, D.T., Lin, K.S., Chen, J.D., et al. (2001). Abnormal Glucose Tolerance in Transfusion-Dependent Beta thalassemic Patients. **Diabetes Care**, 24, 850-854.
- [3] Farmaki, K., Angelopoulos, N., Anagnostopoulos, G. and Gotsis, F. (2006). Effect of enhanced iron chelation therapy on glucose metabolism in patients with β -thalassaemia major. **British Journal of Haematology**, 134, 438-444.
- [4] Dmochowski, K., Finegood, D.T., Francombe, W., Tyler, B. and Zinman, B. (1993). Factors Determining Glucose Tolerance in Patients with Thalassemia Major. **J clin Endocrinol Metab**, 77, 478-483.
- [5] Mahachoke, P., Suprasongsin, J., Likitmaskul, S. and Tanakitjaru, K. (2543). **Endocrinology for Pediatricians**, 212-213. Bangkok: Chaijarearn
- [6] Steensma, D.P., Gibbons, R.J. and Higgs, D.R. (2005). Acquired α -thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. **Blood**, 88(9), 3608-3614.
- [7] Weatherall, D.J. and Clegg, J.B. (1981). **The thalassemia syndromes** (3rd ed.). Oxford London: Blackwell scientific.
- [8] Lukens, J.N. (1993). The thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. In: Lee, GR. (Ed.). **Wintrobe's Clinical Hematology** (9th ed., pp.1102-1145). Pennsylvania: Lea & Febiger, PA Press
- [9] Fucharoen, S. and Winichagoon, P. (1997). Hemoglobinopathies in Southeast Asia: Molecular biology and clinical medicine. **Hemoglobin**, 21, 299-319.
- [10] Piomelli, S., Danoff, S.J. and Becker, M.H. (1969). Prevention of bone malformation and cardiomegaly in cooley's anemia by early hypertransfusion regimen, **Ann NY acad sci**, 165, 427-436.
- [11] Crichton, R.R. and Charleaux-Wauters, M. (1987). Iron transport and storage. **Eur J Biochem**, 164(3), 485-506.

- [12] Anderson, G.J., Darshan, D., Wilkins, S.J. and Frazer, D.M. (2007). Regulation of systemic iron homeostasis: how the body responds to changes in iron demand. **Biometals**, 20(3-4), 665-674.
- [13] Goldenberg, H.A. (1997). Regulation of mammalian iron metabolism: current state and need for further knowledge. **Crit Rev Clin Lab Sci**, 34(6), 529-572.
- [14] Harrison, B.J. and Arosio, P. (1996). The ferritins: molecular properties, iron storage function and cellular regulation. **Biochem Biophys Acta**, 1275(3), 161-203.
- [15] Bolann, B.J. and Ulvik, R.J. (1993). Stimulated decay of superoxide caused by ferritin-bound copper. **FEBS Lett**, 328(3), 263-267.
- [16] Beaumont, C., Leneuve, P., Devaux, I., Scoazec, J.Y., Berthier, M., Loiseau, M.N., et al. (1995). Mutation in iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. **Nat Genet**, 11(4), 444-446.
- [17] Qian, Z.M. and Tang, P.L. (1995). Mechanisms of iron uptake by mammalian cells. **Biochem Biophys Acta**, 1269(3), 205-214.
- [18] Ganz, T. (2005). Heparidin: a regulator of intestinal iron absorption and iron recycling by macrophages. **Best Pract Res Clin Haematol**, 18(2), 171-182.
- [19] Kattamis, A., Papassotiriou, I., Palaiologou, D., Apostolakou, F., Galani, A. Ladis, V., et al. (2006). The effects of erythropoetic activity and iron burden on heparidin expression in patients with thalassemia major. **Haematologica**, 91(6), 809-812.
- [20] Tanno, T., Bhanu, N.V., Oneal, P.A., Goh, S.H., Staker, P. Lee, Y.T., et al. (2007). High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein heparidin. **Nat Med**, 13(9), 1096-1101.
- [21] Aruoma, O.I. and Halliwell, B. (1987). Superoxide-dependent and ascorbate-dependent formation of hydroxyl radical from hydrogen peroxide in the presence of iron. Are lactoferritin and transferrin promoters of hydroxyl-radical generation ?. **Biochem J**, 241(1), 273-278.
- [22] Benatti, U., Morelli, A., Guida, L. and De Flora, A. (1983). The production of activated oxygen species by an interaction of methemoglobin with ascorbate. **Biochem Biophys Res Commun**, 111(3), 980-987.



- [23] Slater, T.F. (1984). Free radical mechanism in tissue injury. **Biochem J**, 222(1), 1-15
- [24] Bacon, B.R., Tavill, A.S., Brittenharm, G.M., Park, C.H. and Recknagel, R.O. (1983). Hepatic lipid peroxidation in vivo in rats with chronic iron overload. **J Clin Invest**, 71(3), 429-439.
- [25] Al-Refaie, F.N., Wickkens, D.G., Wonke, B., Kontoghiorghes, G.J. and Hofbrand, A.V. (1992). Serum non-transferrin-bound iron in beta-thalassemia major patients treated with desferrioxamine and L1. **Br J Haematol**, 82(2), 431-436.
- [26] Gutteridge, J.M.C., Rowley, D.A., Griffiths, E. and Halliwell, B. (1985). Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. **Clin Sci (Lond)**, 68(4), 463-467.
- [27] Wang, W.C., Ahmed, N. and Hanna, M. (1986). Non-transferrin-bound iron in long-term transfusion in children with congenital anemias. **J Pediatr**, 108(4), 552-557.
- [28] Caterina, B.P., Simone, R., Piero, D.S., Huaqing, Z., Maria, D.C, Gian, L.F., et al. (2004). Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. **Haemtologica**, 89(10), 1187-1193.
- [29] Burtis, C.A. and Ashwood, E.R. (2001). **Tietz Fundamentals of Clinical Chemistry**, 437. Missouri: Saunder Elsevier.
- [30] Jaruratanasirikul, S., Chareonmuang, R., Wongcharnchailat, M., Laosonbat, V., Sangsupavanich, P. and Leetanaporn, K. (2008). Prevalence of impaired glucose metabolism with a suboptimal dosage of Iron-chelating therapy. **Eur J Pediatr**, 167, 873-876.
- [31] George, E., Wong, H.B., George, R. and Ariffin, W.A. (1994). Serum ferritin concentrations in transfusion dependent beta-thalassemia, **Singapore Med Journal**, 35, 62-64.
- [32] Livrea, M.A., Tesoriere, L., Pintaudi, A.M., Calabrese, A. and Maggio, A. (1996). Oxidative stress and antioxidant status in β -thalassemia major: Iron overload and depletion of lipid-soluble anti-oxidants. **Blood**, 88, 3608-3614.

- [33] Thakerngpol, K., Fuchroen, S. and Boonyaphipat, P. (1996). Liver injury due to iron overload in thalassemia: histopathologic and ultrastructural studies. **Biometals**, 9, 177-183.
- [34] Davis, B.A. and Porter, J.B. (2000). Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. **Blood**, 95, 1229-1236.
- [35] Finch, C. (1994). Regulators of iron balance in humans. **Blood**, 84, 1697.
- [36] Roeser, H.P., Halliday, J.W. and Sizemore, D.E.A. (1980). Serum ferritin in ascorbic deficiency. **Br J Haematol**, 45, 457.
- [37] Breuer, W., Ermers, M.J., Pootrakul, p., Abramov, A., Hershko, C. and Cabantchik, Z.I. (2001). Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. **Blood**, 97, 792-798.

BIOGRAPHY



BIOGRAPHY

Name – Surname Ampai Pimanprom

Date of Birth 22 May 1977

Address 104/1 Thepkrasattree rd. Talang district, Phuket,
Thailand. 83000

Work Place Blood Bank, Clinical pathology department,
Vachira Phuket Hospital

Position Medical Technologist (MT)

Work Experiences

2001 Blood Bank, Clinical Pathology Department,
Vachira Phuket Hospital Maung District, Phuket,
Thailand.

2000 Laboratory Department, Bangkok Phuket Hospital,
Maung District, Phuket, Thailand

Education Background

2000 B.Sc. (Medical Technology), Chaing Mai University,
Chaing Mai, Thailand.

Publication

Pimanprom, J. (2010). The result of Oral Glucose Tolerance in
transfusion-dependent β -thalassemia patients. In **Proceeding 6th**
Naresuan Research Conference. Phitsanulok: Naresuan
University.

